Teva announces topline results from SPACE study

Teva announced topline results from its Phase 3 SPACE study evaluating the efficacy of Ajovy for the prevention of episodic migraine in children and adolescent patients aged 6-17 years. The trial met its primary end point with Ajovy achieving a statistically significant superior efficacy over 12 weeks of treatment compared to placebo. Safety data was consistent with that observed in adult populations, with no emergent safety signals. Full data from the SPACE study will be presented at a medical meeting later this year. The SPACE data are the first Phase 3 trial evidence of safety and efficacy of an anti-CGRP monoclonal antibody for the treatment of migraine in a pediatric population. The results have particular significance given the lack of preventive migraine treatments approved for use in children and adolescent populations. Teva continues to study the impact of Ajovy in pediatric patients with chronic migraine.